Shandong Xinhua Pharmaceutical (00719) said it expects to record an increase of about 100%-150% in the net profit attributable to the shareholders for the period from 1 January 2017 to 30 June 2017 as compared to the corresponding period in 2016 to about Rmb92 million to Rmb114 million.
During the reporting period, Shandong Xinhua had progressed in product techniques and reduced product costs and grasped the opportunity of the market, actively exploited the market, and expanded of sales volume.
【你點睇】律政司就《願榮光》禁制令上訴得直，法庭批臨時禁制令，你認為能否有效阻截歌曲傳播？► 立即投票
